Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v5-FR
Language English French
Date Updated 2021-10-06 2021-10-01
Drug Identification Number 02482681 02482681
Brand name MORPHINE SULFATE INJECTION, USP MORPHINE SULFATE INJECTION, USP
Common or Proper name Morphine Sulfate Injection, USP 2 mg / mL Vial 1 mL Morphine Sulfate Injection, USP 2 mg / mL Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients MORPHINE SULFATE MORPHINE SULFATE
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 1 mL 1 mL
ATC code N02AA N02AA
ATC description OPIOIDS OPIOIDS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-09-24 2021-09-24
Estimated end date 2021-10-05 2021-10-05
Actual end date 2021-10-05
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be encountering a supply interruption on our Morphine Sulfate Injection, USP 2 mg / mL Vial 1 mL effective today, September 24, 2021 until October 5, 2021.
Health Canada comments